Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2015 01:06 ET | Source: Ablynx

ABLYNX WILL ANNOUNCE ITS FULL YEAR RESULTS 2014 WITH WEBCAST

GHENT, Belgium, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2014 on Thursday 26 February 2015 at 7.00 am CET. The Ablynx management...
January 22, 2015 01:04 ET | Source: Ablynx

ABLYNX SUCCESSFULLY OPPOSES PATENT APPEAL CASE BY DOMANTIS (GSK)

GHENT, Belgium, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has been successful in opposing the appeal lodged by Domantis (now a member of the...
January 21, 2015 01:05 ET | Source: Ablynx

ABLYNX ANNOUNCES WARRANT EXERCISE

GHENT, Belgium, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that...
January 07, 2015 01:09 ET | Source: Ablynx

ABLYNX TO PRESENT AT THE 33rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

GHENT, Belgium, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that its CEO, Dr Edwin Moses, will present at the 33rd Annual J.P. Morgan Healthcare Conference on...
December 24, 2014 01:05 ET | Source: Ablynx

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION GHENT, Belgium, Dec. 24, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX], today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...
December 17, 2014 01:09 ET | Source: Ablynx

ABLYNX OPENS RECRUITMENT FOR FIRST-IN-INFANT PHASE IIa STUDY WITH ITS ANTI-RSV NANOBODY, ALX-0171

ALX-0171 is a first-in-class anti-RSV Nanobody® administered via inhalation ALX-0171 was well tolerated in multiple Phase I clinical studies in adults ALX-0171 has demonstrated a...
December 08, 2014 10:06 ET | Source: Ablynx

ADDITIONAL CLINICAL DATA FROM THE PHASE II STUDY WITH ABLYNX'S ANTI-vWF NANOBODY, CAPLACIZUMAB, PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

Caplacizumab is a potential first-in-class therapeutic with Orphan Drug status Caplacizumab, in addition to plasma exchange and immunosuppressive therapy, has the potential to become an...
November 26, 2014 01:06 ET | Source: Ablynx

ABLYNX DEMONSTRATES BIOEQUIVALENCE BETWEEN LIQUID AND LYOPHILISED FORMULATIONS OF ITS ANTI-vWF NANOBODY, CAPLACIZUMAB

Caplacizumab has first-in-class potential for the treatment of thrombotic thrombocytopenic purpura (TTP) On track to start Phase III study in patients with acquired TTP in mid-2015 GHENT,...
November 18, 2014 01:06 ET | Source: Ablynx

ABLYNX APPOINTS JOHAN HEYLEN AS CHIEF COMMERCIAL OFFICER

GHENT, Belgium, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced the appointment of Johan Heylen as Chief Commercial Officer. Mr Heylen will assume responsibility for...
November 17, 2014 01:04 ET | Source: Ablynx

ABLYNX TO PRESENT AT THE JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE IN LONDON

GHENT, Belgium, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present at the Jefferies 2014 Global Healthcare Conference at the Waldorf Hilton in...